摘要:

SummaryThe methods available to the clinical pharmacologist for evaluation of anti-aggregating compounds in man are briefly presented. A distinction is made betweenex vivomethods (in vitro evaluation of the modified platelet adhesion or aggregation following drug administration) and strictlyin vivotechniques (the bleeding time and the platelet survival time). The effects of dipyridamole, sulfinpyrazone, acetylsalicylic acid, clofibrate and dextrans on these indices of platelet behaviour are briefly described. It is emphasized that platelet function is altered in a very similar fashion following administration of either dipyridamole or sulfinpyrazone; acetylsalicylic acid however modifies platelet behaviour in a completely different manner. A possible synergism between these two types of compounds has been proposed.

ISSN:1784-3286    

DOI:10.1080/17843286.1975.11716998

出版商:Taylor&Francis    

年代:1975

数据来源: Taylor

摘要:

SummaryDuring urokinase thrombolytic treatment, for acute myocardial infarction and massive pulmonary embolism, the authors observed the apparition or the exaggeration of platelet hyperaggregation. In vitro experiments reproduced this effect with several fibrinolytic enzymes, including streptokinase and urokinase. Hyperaggregation is obtained with normal plasma, without the addition of the usual aggregation inductors. The possible mechanisms of this side effect of thrombolytic treatments are mentioned. Although the eventual role this iatrogenic hyperaggregation may play in the recurrence of pulmonary embolism or in the secondary extension of myocardial infarction is unknown, it is wise to correct it. Dipyridamole at the daily dose of 60 mg intravenously has shown itself to be useful.

ISSN:1784-3286    

DOI:10.1080/17843286.1975.11716999

出版商:Taylor&Francis    

年代:1975

数据来源: Taylor

摘要:

SummaryMany mechanisms may be involved in the role of platelets in thrombogenesis and therefore more than one platelet blocking agent may be required to prevent thrombosis. However, the action of blocking agents must be established independently before they are studied in combination.The action of one agent–aspirin (which, in fact, blocks the platelet release action and does not interfere with primary aggregation)–is studied more closely here in four clinical conditions: venous thrombosis, arterial thrombosis, atherosclerosis, and in one case of multiple chronic microemboli with resultant intensive lung destruction. The evidence obtained so far is not conclusive, and more research is needed, but the future of this, and other, anti-platelet agents looks promising.

ISSN:1784-3286    

DOI:10.1080/17843286.1975.11717000

出版商:Taylor&Francis    

年代:1975

数据来源: Taylor

摘要:

Summary1. Dipyridamole normalizes the pathological increased platelet turnover in patients with arterial thromboembolism.2. When given simultaneously with anticoagulants, Dipyridamole therapy definitely reduces the number of arterial emboli in patients with artificial heart vaives.3. A combined treatment of chronic renal diseases with Dipyridamole and anticoagulants results in unquestionable improvement of the clinical symptoms and the laboratory findings.Such a combination therapy with the addition of cyclophosphamide, given for 3 years, has demonstrated life-prolonging effects in patients with mesangio-capillary glomerulonephritis.4. In cases of thrombotic microangiopathy or hemolytic-uremic syndrom, the combined use of Dipyridamole and acetylsalicylic acid has resulted in dramatic improvements in the clinical symptoms and laboratory findings.5. In observations over a 3-year period, patients with heart transplants treated with Dipyridamole and anticoagulants as compared with the customary treatment clearly show longer survival time and significantly less advance of any arteriosclerotic change in the coronary vessels.6. Following surgical intervention, treatment with a combination of Dipyridamole and acetylsalicylic acid results in a distinct reduction in the rate of thrombosis as determined with labelled fibrinogen.

ISSN:1784-3286    

DOI:10.1080/17843286.1975.11735722

出版商:Taylor&Francis    

年代:1975

数据来源: Taylor

ISSN:1784-3286    

DOI:10.1080/17843286.1975.11717002

出版商:Taylor&Francis    

年代:1975

数据来源: Taylor

ISSN:1784-3286    

DOI:10.1080/17843286.1975.11717003

出版商:Taylor&Francis    

年代:1975

数据来源: Taylor

ISSN:1784-3286    

DOI:10.1080/17843286.1975.11717004

出版商:Taylor&Francis    

年代:1975

数据来源: Taylor

ISSN:1784-3286    

DOI:10.1080/17843286.1975.11717005

出版商:Taylor&Francis    

年代:1975

数据来源: Taylor